Flavone acetic acid (FAA) showed impressive effects against murine solid tumours but no activity in clinical studies. The mechanism of action in mice may involve damage to tumour vasculature or immunomodulation, and these effects may be species-specific. Alternatively, concentrations of FAA achieved in mouse tumours may be higher than in human tumours. It is important to resolve this issue since it raises important questions about the relevance of in vitro versus in vivo tumour screens and the development of FAA analogues. As part of a Cancer Research Campaign Phase II study of metastatic melanoma in which 8.4 g m 2 FAA was given as a 6 h infusion, six tumour biopsies were obtained from four patients. FAA tumour concentrations were determined by HPLC and compared with subcutaneous murine solid tumours within the same analytical laboratory. Tumour/plasma percentages (range 26-61%; mean ± SD, 43.9 ± 11.4%) were similar to those in mice, as was the area under the curve (AUC) extrapolated to infinity and the AUC above the putative activity threshold of 100 jig ml . We conclude that the exposure of drug-refractory human melanoma tissue to FAA was comparable to that of sensitive mouse tumours. This suggests that reduced penetration of FAA into human tumours is unlikely to explain the lack of antitumour activity observed in clinical studies and that differences in mechanism of action are predominant.
Flavone acetic acid (FAA) is a synthetic flavonoid with impressive activity in preclinical testing against murine tumours including some quite refractory to conventional agents (Corbett et al., 1986; Plowman et al., 1986; Bibby et al., 1988) . It attracted substantial interest because of the likely involvement of a unique mechanism of action (Cummings & Smyth, 1989; Workman, 1989; Bibby, 1991) . The precise mode of anti-tumour cytotoxicity is uncertain but may involve indirect effects (Finlay et al., 1988) on tumour vasculature (Eveloch et al., 1988; Zwi et al., 1989; Bibby et al., 1989; Murray et al., 1989) or immunological mechanisms Urba et al., 1988; .
Despite encouraging preclinical results, FAA proved completely ineffective in Phase I and II clinical trials (Kerr et al., 1987; 1989; Kaye et al., 1990) . The reason for this is unclear. Differences in pharmacokinetics have been observed between mouse, dog and man (Cummings & Smyth, 1989 ; Kerr et al., 1989; Zaharko et al., 1986 , Damia et al., 1988 Gouyette et al., 1988; Chabot et al., 1989) . However, plasma concentrations similar to those in mice (>100 gLg ml-l) were observed in human plasma at the doses used in the Phase II studies. Therefore differences relating to tumour penetration may be responsible. Alternatively, the vascular or immunomodulatory mechanisms may depend on species-specific receptors. It is important to resolve this issue since it raises questions about the relevance of in vitro versus in vivo tumour screens and the development of FAA analogues.
We report the human tumour FAA concentrations achieved in patients with metastatic melanoma treated in the Cancer Research Campaign Phase II trial and compare them with levels observed in mouse tumours in the same analytical laboratory. Taken together with those of Damia et al. (1990) the results show that reduced penetration of FAA into human tumours is unlikely to explain the lack of activity in clinical studies and that differences in mechanism of action may predominate.
Methods
Human studies Patients Nine patients (six female, three male, age range 28-69 years) were entered into the CRC Phase II study of FAA in malignant melanoma (Kerr et al., 1989 concentrations at the end of infusion and after 30 m were 378 and 306 gig ml-. The average elimination half life (tp) was 5.4 h and the AUCO. was 3612 gig ml-' h. Pharmacokinetics were closely comparable to those reported in the Phase I studies (Kerr et al., 1987) . The mean AUC above the postulated activity threshold (Zaharko et al., 1986) Pharmacokinetic analysis Pharmacokinetic parameters were calculated by nonlinear regression analysis using Subroutine VCO5AD of the Harwell Subroutine Library. Parameters were derived from standard equations (Wagner, 1975) . Area under the curve (AUC) above 100 gig ml-' was calculated using the trapezoidal method.
Tumour blood flow assessment Relative tumour perfusion was assayed in mice bearing KHT sarcomas after ip injection of 200 mg kg-' (600 mg M-2) FAA, by 86rubidium (Sapirstein, 1958 elimination ti of 5.8 h. At 1-6 h the tumour/plasma % was constant with a mean of 73%. Thereafter, the tumour concentration fell more slowly than the plasma concentration, such that tumour exceeded plasma at these late times. Tumour/plasma percentages at 12 and 24h after injection were 452% and 852% respectively. Similar results were obtained in a repeat experiment using 200 mg kg-'
(600 mg m2) FAA (data not shown). Parallel studies of KHT tumours after 200 mg kg-' (600 mg m 2) ip FAA showed a rapid decline in the relative tumour blood flow. A nadir of 5% of control was observed at 6 h, followed by a slow recovery to 20% at 24 h ( Figure  2B ). No significant alteration occurred in a range of normal tissues (data not shown). Doses of 200 and 250 mg kg-' (600-750 mg M-2) FAA ip resulted in regrowth delays of around 3-5 days in KHT sarcomas, compatible with the previously reported efficacy of FAA in murine tumours (Corbett et al., 1986; Plowman et al., 1986; Bibby et al., 1988) .
In contrast to plasma (Cummings et al., 1988; Cummings & Smyth, 1989) , no metabolites of FAA were detected in either human or mouse tumours. 
Discussion
One possible explanation for the marked discrepancy between the impressive effects of FAA against transplanted murine solid tumours (Corbett et al., 1986; Plowman et al., 1986; Bibby et al., 1988) and the absence of activity in human studies (Kerr et al., 1987; 1989; Kaye et al., 1990 ) is a difference in tumour drug exposure between mice and humans. This study has shown a close parallel between the plasma exposures in the two species. Mean AUCO-,, was 3612 ,.g ml' h in the patients and 2985 yg ml-' h mice. Similarly, above the postulated threshold of 100ILgml-l (Zaharko et al., 1986 ) the plasma drug exposures were highly comparable, being 1865 and 1816 fg ml-' h in humans and mice respectively. Tumour/plasma percentages were found to be marginally higher in the case of mouse tumours (48-63%) but of similar magnitude to that observed in humans (mean 47.5%) at early time points. The peak (30 min) tumour concentrations in murine tumours (300 lg g-1) were higher by a factor of 2 compared with the melanoma deposits over the first hour after EOI (150 fig g-1) . After 6 h, there was a reproducible and marked elevation in the tumour/plasma percentages for the KHT tumour. This was not seen in the single melanoma biopsy obtained at 12 h, where the value was 25%. The elevation in the tumour/plasma percentages for the KHT tumour coincided with the abrupt fall in tumour blood flow, as noted previously in sensitive mouse solid tumours (Corbett et al., 1986; Plowman et al., 1986; Bibby et al., 1988 ). Thus, it seems possible that the rise in tumour/plasma percentages was due to the trapping of FAA in KHT tumours as a result of the reduction of blood flow.
Although it was only possible to obtain a single late time point in the human tumour study, the relatively low value there suggested that this trapping effect may not be seen in man.
It is particularly interesting to compare the exposures to FAA in the mouse and human tumours. The AUCO, for the murine KHT tumour was 2790 ltg g-' h. This is similar to that of 1733 jig g-' h for the human melanomas estimated as the product of the average plasma AUCO-,0, and the mean tumour/plasma ratio of 0.48. The corresponding values above the putative activity threshold showed even closer agreement at 983 fig g-' h for the mouse KHT tumour and 895 ± 377(SD) ttg g-I h for human melanomas. Thus the mouse and the predicted human FAA exposures are very similar. We have to emphasise however that we have only a single human melanoma value for time points beyond 1 h and further data for later times would be useful to confirm our prediction.
The mouse plasma and tumour exposures obtained in the present study are similar to those reported previously (Damia et al., 1988; Chabot et al., 1989) . For example, Damia et al.
(1988) observed a plasma AUCo_0 (± SE) of 2021 ± 166 tg ml-' h and a tissue/plasma % for the mouse PAN/03 tumour of 57% after 200 mg kg-' (600 mg m-2) FAA. The Mario Negri group also reported the only other published data for human tumour FAA levels (Damia et al., 1990) . They obtained biopsies of primary or metastatic tumour for six patients, in all cases 2 h after a 1 h infusion of 4.8 g m-2 FAA in an EORTC ECTG study. Tumour/plasma percentages ranged from 25-80% and the mean of 45.8 (± 24.5 SD)% was almost identical to the present study.
Taken together with previous experience, our studies appear to rule out inadequate tissue exposure as a cause of the lack of activity of FAA in human compared to mouse tumours. A species-specific mechanism, presumably involving the tumour vasculature or the immune system, may be responsible. Alternatively, the various effects of FAA seen in rodents may be a feature of transplantable tumours, rather than a species difference per se.
